SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint ...

SleepRes, Inc., a sleep technology company focused on reimagining therapy for sleep breathing disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance ...

New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to ...

The utilization of positive airway pressure (PAP) therapy is associated with reduced rates of mortality and incidence of major adverse cardiovascular events (MACEs) in older adults with obstructive ...

Please provide your email address to receive an email when new articles are posted on . Researchers pooled together randomized controlled trials and non-randomized controlled studies reporting on CPAP ...

Please provide your email address to receive an email when new articles are posted on . Adults with OSA and obesity receiving tirzepatide had reductions in apnea-hypopnea index events and body weight.

Positive airway pressure (PAP) therapy devices are widely used to treat many of the approximately 30 million people managing sleep apnea in the United States. CPAP (Continuous positive airway pressure ...

A new study from San Diego-based sleep monitoring company ResMed shows that patients on positive airway pressure (PAP) therapy for their sleep apnea are more likely to be compliant when they manage ...